Search

A blood test at the age of 60 can accurately predict the risk that a man will die from prostate cancer within the next 25 years, according to researchers at Memorial Sloan Kettering Cancer Center, in New York, and Lund University, in Sweden. The findings were published today online in the British Medical Journal.

… Tuesday, September 14, 2010 A blood test at the age of 60 can accurately predict the risk that a man will die from prostate cancer within the next 25 years, according to researchers at Memorial Sloan Kettering Cancer Center, in New York, and Lund University, in Sweden. The findings, published today online

Six students have successfully defended their dissertations and will receive their PhD degrees at Commencement on May 10.

… Monday, April 29, 2013 Six students at the Gerstner Sloan Kettering Graduate School of Biomedical Sciences have successfully defended their dissertations. As part of Memorial Sloan Kettering’s 34th annual academic convocation on May 10, the Louis V. Gerstner, Jr. Graduate School of Biomedical Sciences

Dr. Nai-Kong V. Cheung, MD, PhD, the Enid A. Haupt Chair in Pediatric Oncology at MSK, was honored by the Advances in Neuroblastoma Research Association (ANRA) with its 2025 lifetime achievement award. An esteemed physician-scientist, Dr. Cheung leads a laboratory in Memorial Hospital Research Laboratories at MSK, which is focused on engineering antibodies and immune cells to treat both solid tumors and liquid tumors in children.

… Thursday, July 17, 2025 Dr. Nai-Kong V. Cheung, MD, PhD, the Enid A. Haupt Chair in Pediatric Oncology at MSK, was honored by the Advances in Neuroblastoma Research Association (ANRA) with its 2025 lifetime achievement award. An esteemed physician-scientist, Dr. Cheung leads a laboratory in Memorial

Computer models suggest breast cancer screening guidelines for people with mutations in the genes ATM, CHEK2, and PALB2.

… Thursday, February 17, 2022 Many people have heard of mutations in the BRCA1 and BRCA2 genes that are linked to an increased risk of certain cancers, including breast cancer . But there are other, less well-known genes in which hereditary mutations can also increase breast cancer risk, including ATM

MSK chemists are focusing on developing small-molecule drugs to target KRas, an important cancer protein.

… Wednesday, May 24, 2017 Summary MSK chemists are focusing on developing small-molecule drugs to target KRas, an important cancer protein. KRas is linked to nearly 30% of all cancers. Drug development is a complicated task. In the era of targeted therapies for cancer, medicinal chemists seek to design

Dr. Mini Kamboj, MSK’s Chief Medical Epidemiologist, explains what people with cancer and their caregivers need to know about measles and the MMR (measles, mumps, and rubella) vaccine.

… Monday, February 9, 2026 More than 25 years ago, public health officials declared that measles had been eliminated in the United States. Today, however, due to declining vaccination rates, measles cases have surged to their highest levels in decades. Mini Kamboj, MD , MSK’s Chief Medical Epidemiologist

… Wednesday, March 10, 2010 Team GSK Raises Money for Rare Cancer Research Dimiter Tassev Team GSK Captain Dimiter Tassev On Feburary 6, teams of Gerstner Sloan Kettering students and faculty joined 2,500 indoor cyclists from New York and Chicago to raise more than $2.4 million to support rare cancer research

The drug, sotorasib, is targeted against a cancer-causing protein that has long been considered an “undruggable” target.

… Sunday, September 20, 2020 Summary In a study of people with lung cancer whose tumors contained the mutation targeted by sotorasib, 52 of 59 patients experienced disease control, which means that their tumors stopped growing. Update: On January 30, 2021, Memorial Sloan Kettering lung cancer expert Bob

A new tool developed by MSK scientists allows users to map metabolic data from kidney cancer tumors.

… Friday, February 5, 2016 Summary Changes in cell metabolism are increasingly recognized as an important way tumors develop and progress, yet these changes are hard to measure and interpret. A new tool designed by MSK scientists allows users to identify metabolic changes in kidney cancer tumors that may

Awarded annually since 1955, the Sloan Research Fellowships honor exceptional U.S. and Canadian researchers whose creativity, leadership, innovation, and research accomplishments make them stand out as the next generation of leaders.

… Thursday, February 22, 2024 Memorial Sloan Kettering Cancer Center (MSK)  is proud to announce that  Yael David, PhD , chemical biologist leading The Yael David Lab and Associate Member of the Chemical Biology Program , has been selected as a 2024 Alfred P. Sloan Research Fellow in Chemistry. Dr. David